About Erwinaze^™

A newly approved asparaginase for use in patients with acute lymphoblastic leukemia (ALL)

Erwinaze, (asparaginase Erwinia chrysanthemi), unlike other currently marketed asparaginases, is derived from Erwinia chrysanthemi and has been recently approved by the Food and Drug Administration (FDA) under the trade name Erwinaze.
Full prescribing information can be found by clicking here

Erwinaze is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL who have developed hypersensitivity to E. coli-derived asparaginases.

Read about the key characteristics of Erwinaze, how it may be used to maintain asparagine depletion in patients who have developed antibodies to E.coli-derived asparaginase, and how dosing guidelines vary from those for existing asparaginase products.

Download Erwinaze information designed for patients and caregivers here.

CONTRAINDICATIONS: Hx of serious hypersensitivity to Erwinaze, including anaphylaxis; Hx of serious pancreatitis, thrombosis or hemorrhage with prior L-asparaginase therapy.

WARNINGS AND PRECAUTIONS: Discontinue if serious hypersensitivity, including anaphylaxis, OR severe or hemorrhagic pancreatitis occur. Monitor glucose (intolerance may not be reversible); With thrombosis and hemorrhage: discontinue until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women.

COMMON (≥ 1%) ADVERSE REACTIONS: Serious hypersensitivity, including anaphylaxis, pancreatitis, abnormal transaminases, coagulation abnormalities, nausea, vomiting, and hyperglycemia.

Please see full Prescribing Information.

This site is only intended for residents of the United States.